Commerce Bank Purchases 361 Shares of DexCom, Inc. (NASDAQ:DXCM)

Commerce Bank increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1.9% during the 4th quarter, HoldingsChannel reports. The firm owned 19,295 shares of the medical device company’s stock after buying an additional 361 shares during the period. Commerce Bank’s holdings in DexCom were worth $1,501,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the business. Virtu Financial LLC purchased a new position in DexCom in the third quarter worth about $1,020,000. Pine Valley Investments Ltd Liability Co increased its position in shares of DexCom by 59.2% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company’s stock valued at $381,000 after purchasing an additional 2,111 shares during the last quarter. World Investment Advisors LLC purchased a new stake in DexCom during the 3rd quarter valued at $2,351,000. Wilmington Savings Fund Society FSB bought a new stake in DexCom in the third quarter worth $381,000. Finally, Tidal Investments LLC boosted its stake in DexCom by 68.0% during the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock worth $2,463,000 after buying an additional 14,872 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Cfra Research upgraded shares of DexCom to a “hold” rating in a report on Friday, March 21st. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Mizuho assumed coverage on DexCom in a research report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price objective on the stock. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

DexCom Trading Down 3.6 %

DexCom stock opened at $66.11 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market cap of $25.92 billion, a PE ratio of 46.23, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The stock has a 50-day moving average of $74.62 and a two-hundred day moving average of $76.74. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.